<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397590</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FMS-CT-117</org_study_id>
    <nct_id>NCT02397590</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetic Interaction Between Fimasartan and Atorvastatin in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Six-sequence, Three-period, Multiple Dosing Study to Evaluate the Pharmacokinetic Interaction Between Fimasartan and Atorvastatin in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I clinical trial to compare the pharmacokinetics and safety of
      fimasartan/Atorvastatin combination tablet and coadministration of fimasartan and
      Atorvastatin in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After subjects have signed informed consent voluntarily, they go through screening period for
      within 21 days.

      Group 1 period 2 period 3 period A F A F+A B F F+A A C A F+A F D A F F+A E F+A F A F F+A A F

      At each period taking Fimasartan, subjects of this Group have blood sampling 0, 0.25, 0.5,
      0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hour after medication(15 times in each
      period).

      At each period taking Atorvastatin, subjects of this Group have blood sampling 0, 0.5, 1,
      1.5, 2, 3, 4, 6, 8, 12, 24 and 48 hour after medication(12 times in each period).

      At each period taking Fimasartan and Atorvastatin, subjects of this Group have blood sampling
      0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hour after medication(15 times
      in each period).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC tau,ss</measure>
    <time_frame>Time Frame: 0~48 hour after medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>Time Frame: 0~48 hour after medication</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fimasartan (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_label>C Group</arm_group_label>
    <arm_group_label>D Group</arm_group_label>
    <arm_group_label>E Group</arm_group_label>
    <arm_group_label>F Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_label>C Group</arm_group_label>
    <arm_group_label>D Group</arm_group_label>
    <arm_group_label>E Group</arm_group_label>
    <arm_group_label>F Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subject, aged 19- 50 years at screening.

          2. Body weight between 19.0 and 28.0 of ideal body weight (IBW)(kg) = {height (cm) - 100}
             * 0.9

        Exclusion Criteria:

          1. History of any illness that may affect the absorption, distribution, metabolism or
             excretion (hepatobiliary, renal, cardiovascular, endocrine (e.g., hypothyroidism),
             respiratory, gastrointestinal, hemato-oncology, central nervous system, psychiatric
             and musculoskeletal system)

          2. Hypotension (systolic ≤ 100 mmHg or diastolic ≤ 65 mmHg) or hypertension (systolic ≥
             140 mmHg or diastolic ≥ 90 mmHg), measured at screening

          3. Evidence of hereditary disease, including galactose intolerance, Lapp lactase
             deficiency, or glucose-galactose malabsorption.

          4. History of gastrointestinal disease (i.g., Crohn's disease, active peptic ulcer) or
             resection operation that may affect the absorption of the study drug (excluding simple
             appendectomy or herniorrhaphy)]

          5. Participation in any other study within 2 months prior to the first administration of
             study drug (The finish time of previous study is the day of the last administration of
             study drug)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>July 21, 2015</last_update_submitted>
  <last_update_submitted_qc>July 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fimasartan</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

